Enterprise Value

3.046B

Cash

437.1M

Avg Qtr Burn

-27.87M

Short % of Float

23.27%

Insider Ownership

17.14%

Institutional Own.

70.65%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Sunosi® (solriamfetol) Details
Mental health, Excessive daytime sleepiness

Approved

Quarterly sales

NDA

Resubmission

NDA

Submission

Solriamfetol Details
Attention deficit hyperactivity disorder

Phase 3

Data readout

Phase 3

Data readout

AXS-12 (reboxetine) (NE reuptake inhibitor) Details
Narcolepsy

Big Mover™

Susp. Mover™

Phase 3

Data readout

Solriamfetol Details
Shift work disorder

Phase 3

Initiation

Solriamfetol Details
Binge eating disorder

Phase 3

Initiation

Phase 2/3

Initiation